SAN DIEGO, Sept. 8, 2011 (GLOBE NEWSWIRE) -- BioMedTracker, the leading provider of competitive intelligence and investment analytics on the biotech/pharmaceutical sector, today announced the recent launch of its new service, AdComm Insight. This service allows subscribers to quickly gain an understanding of the potential outcomes of future FDA Advisory Committee meetings before they happen.
AdComm Insight tracks who is voting on each upcoming panel meeting and displays in an easy-to-read grid how they have voted in past meetings on the primary questions related to approvability. This gives subscribers a detailed snapshot of who the relatively easy or difficult yes votes are and who has voted closest with the consensus. Clients can dig in deeper into any panel member by simply clicking into their personal profile, which contains biographical information, term of membership, CV/Resume details, and a comprehensive question and answer history for that panel member.
"As advisory panel meeting outcomes have become more important and panel membership inclusion has become restrictive based on new conflicts rules, knowing who the members are before they vote has never been more critical," said Robert Kyle, CEO of Sagient Research. "We launched the AdComm Insight service to give our customers unparalleled access to this predictive information within the easy-to-use BioMedTracker drug database platform to help them better predict the outcomes of these ever more important FDA Advisory Panel meetings."
In conjunction with the launch of the AdComm Insight Service, BioMedTracker is currently offering trials to interested firms. Any biotech/pharmaceutical investor or industry professional who is interested in accessing this trial may contact BioMedTracker by email at BioMedsubscribe@sagientresearch.com or call 858-200-2390.
About BioMedTracker
BioMedTracker is an independent research service that offers proprietary clinical assessments and patient-based revenue forecasts of developmental drugs within a comprehensive and intuitive drug information database. Clients from the pharmaceutical, biotech, and investment industries rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.
The Sagient Research Systems logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7294